home / stock / nrsn / nrsn quote
Last: | $1.08 |
---|---|
Change Percent: | 5.36% |
Open: | $1.06 |
Close: | $1.08 |
High: | $1.13 |
Low: | $0.98 |
Volume: | 1,410,657 |
Last Trade Date Time: | 07/01/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.08 | $1.06 | $1.08 | $1.13 | $0.98 | 1,410,657 | 07-01-2024 |
$1.12 | $1.02 | $1.12 | $1.14 | $0.9589 | 509,956 | 06-28-2024 |
$1.02 | $0.87 | $1.02 | $1.04 | $0.87 | 211,575 | 06-27-2024 |
$0.8516 | $0.8074 | $0.8516 | $0.8516 | $0.698 | 132,146 | 06-26-2024 |
$0.846 | $0.84 | $0.846 | $0.85 | $0.8001 | 32,320 | 06-25-2024 |
$0.845272 | $0.841 | $0.845272 | $0.89 | $0.8 | 122,570 | 06-24-2024 |
$0.898 | $0.91 | $0.898 | $0.94 | $0.821 | 72,460 | 06-21-2024 |
$0.9 | $0.93 | $0.9 | $0.952125 | $0.84 | 57,337 | 06-20-2024 |
$0.92 | $0.9223 | $0.92 | $0.96 | $0.882 | 28,682 | 06-19-2024 |
$0.92 | $0.9223 | $0.92 | $0.96 | $0.882 | 28,682 | 06-18-2024 |
$0.932917 | $0.978 | $0.932917 | $0.9999 | $0.8283 | 274,656 | 06-17-2024 |
$0.97 | $1.04 | $0.97 | $1.04 | $0.9524 | 64,610 | 06-14-2024 |
$1.02 | $1.06 | $1.02 | $1.0691 | $1 | 32,230 | 06-13-2024 |
$1.03 | $1 | $1.03 | $1.1299 | $1 | 127,521 | 06-12-2024 |
$1.01 | $1.04 | $1.01 | $1.0513 | $0.96 | 51,151 | 06-11-2024 |
$1.04 | $1.08 | $1.04 | $1.085 | $0.95 | 195,473 | 06-10-2024 |
$1.1 | $1.116 | $1.1 | $1.13 | $1.06 | 85,271 | 06-07-2024 |
$1.14 | $1.2 | $1.14 | $1.21 | $1.1 | 24,433 | 06-06-2024 |
$1.17 | $1.18 | $1.17 | $1.2299 | $1.1007 | 75,286 | 06-05-2024 |
$1.18 | $1.11 | $1.18 | $1.2492 | $1.1 | 189,574 | 06-04-2024 |
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
5.36%Change Percent:
NeuroSense Therapeutics Ltd. Company Name:
NRSN Stock Symbol:
NASDAQ Market:
NeuroSense Therapeutics Ltd. Website:
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug PR Newswire Disease progression was slowed by 36% (p=...
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results PR Newswire Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term ...
NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal PR Newswire CAMBRIDGE, Mass. , June 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative ...